
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
LRCH4 (leucine rich repeats and calponin homology domain containing 4) encodes a protein containing leucine-rich repeats (LRR) at its amino terminus that contribute to ligand binding. Its carboxyl-terminal region may function as a membrane anchor. The structural organization of LRCH4 suggests a receptor-like role, supporting potential functions in ligand recognition and membrane-associated cellular interactions.
JAR is a human choriocarcinoma cell line established from a trophoblastic tumor of the placenta of a 24-year-old woman. The cell line originates from a male fetus and represents a trophoblast-derived tumor model. JAR is used for studies of placental biology, trophoblast differentiation, and mechanisms involved in gestational cancers.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001289934
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?